Longterm outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil

Jianming Ren, Dong H. Shin, John M. O'Grady, Yong Yeon Kim, Mark S. Juzych, Bret A. Hughes, Chaesik Kim, Bernice K. Glover

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To evaluate the long-term effect of adjunctive subconjunctival 5-fluorouracil (5-FU) on the filtration outcome of primary glaucoma triple procedure (PGTP) in primary open-angle glaucoma (POAG) patients. Methods: Seventy-four POAG patients were randomly assigned to PGTP alone (36 patients) or PGTP with adjunctive subconjunctival 5-FU (5.0±1.3 injections of 5 mg each, total of 24.8 mg) (38 patients). After surgery, the patients were examined at regular intervals for intraocular pressure (IOP), visual acuity, medical therapy requirements, and complications. Surgical success was defined as IOP ≤20 mmHg on postoperative medication ≤1 without additional glaucoma surgery. Results: Over an average follow-up (±SD) of 45.3 ± 25.0 months, both 5-FU and control groups maintained significant improvement of IOP control and visual acuity. However, there were no statistically significant differences between the 5-FU and control groups with respect to postoperative IOP, number of glaucoma medications, visual acuity outcome, and success rate overall or in selected patients with one or more of the risk factors for filtration failure. Conclusions: The use of low-dose subconjunctival 5-FU (mean dosage of 24.8 mg in 5.0 ± 1.3 injections) as an adjunct did not significantly improve the long-term filtration outcome of PGTP in POAG patients.

Original languageEnglish
Pages (from-to)501-506
Number of pages6
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume236
Issue number7
DOIs
Publication statusPublished - 1998 Jul 1
Externally publishedYes

Fingerprint

Fluorouracil
Glaucoma
Intraocular Pressure
Visual Acuity
Control Groups
Injections
Primary Open Angle Glaucoma

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Longterm outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil. / Ren, Jianming; Shin, Dong H.; O'Grady, John M.; Kim, Yong Yeon; Juzych, Mark S.; Hughes, Bret A.; Kim, Chaesik; Glover, Bernice K.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 236, No. 7, 01.07.1998, p. 501-506.

Research output: Contribution to journalArticle

Ren, Jianming ; Shin, Dong H. ; O'Grady, John M. ; Kim, Yong Yeon ; Juzych, Mark S. ; Hughes, Bret A. ; Kim, Chaesik ; Glover, Bernice K. / Longterm outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil. In: Graefe's Archive for Clinical and Experimental Ophthalmology. 1998 ; Vol. 236, No. 7. pp. 501-506.
@article{2c60f38d9d12458c985e351c7ee631ed,
title = "Longterm outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil",
abstract = "Purpose: To evaluate the long-term effect of adjunctive subconjunctival 5-fluorouracil (5-FU) on the filtration outcome of primary glaucoma triple procedure (PGTP) in primary open-angle glaucoma (POAG) patients. Methods: Seventy-four POAG patients were randomly assigned to PGTP alone (36 patients) or PGTP with adjunctive subconjunctival 5-FU (5.0±1.3 injections of 5 mg each, total of 24.8 mg) (38 patients). After surgery, the patients were examined at regular intervals for intraocular pressure (IOP), visual acuity, medical therapy requirements, and complications. Surgical success was defined as IOP ≤20 mmHg on postoperative medication ≤1 without additional glaucoma surgery. Results: Over an average follow-up (±SD) of 45.3 ± 25.0 months, both 5-FU and control groups maintained significant improvement of IOP control and visual acuity. However, there were no statistically significant differences between the 5-FU and control groups with respect to postoperative IOP, number of glaucoma medications, visual acuity outcome, and success rate overall or in selected patients with one or more of the risk factors for filtration failure. Conclusions: The use of low-dose subconjunctival 5-FU (mean dosage of 24.8 mg in 5.0 ± 1.3 injections) as an adjunct did not significantly improve the long-term filtration outcome of PGTP in POAG patients.",
author = "Jianming Ren and Shin, {Dong H.} and O'Grady, {John M.} and Kim, {Yong Yeon} and Juzych, {Mark S.} and Hughes, {Bret A.} and Chaesik Kim and Glover, {Bernice K.}",
year = "1998",
month = "7",
day = "1",
doi = "10.1007/s004170050112",
language = "English",
volume = "236",
pages = "501--506",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Longterm outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil

AU - Ren, Jianming

AU - Shin, Dong H.

AU - O'Grady, John M.

AU - Kim, Yong Yeon

AU - Juzych, Mark S.

AU - Hughes, Bret A.

AU - Kim, Chaesik

AU - Glover, Bernice K.

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Purpose: To evaluate the long-term effect of adjunctive subconjunctival 5-fluorouracil (5-FU) on the filtration outcome of primary glaucoma triple procedure (PGTP) in primary open-angle glaucoma (POAG) patients. Methods: Seventy-four POAG patients were randomly assigned to PGTP alone (36 patients) or PGTP with adjunctive subconjunctival 5-FU (5.0±1.3 injections of 5 mg each, total of 24.8 mg) (38 patients). After surgery, the patients were examined at regular intervals for intraocular pressure (IOP), visual acuity, medical therapy requirements, and complications. Surgical success was defined as IOP ≤20 mmHg on postoperative medication ≤1 without additional glaucoma surgery. Results: Over an average follow-up (±SD) of 45.3 ± 25.0 months, both 5-FU and control groups maintained significant improvement of IOP control and visual acuity. However, there were no statistically significant differences between the 5-FU and control groups with respect to postoperative IOP, number of glaucoma medications, visual acuity outcome, and success rate overall or in selected patients with one or more of the risk factors for filtration failure. Conclusions: The use of low-dose subconjunctival 5-FU (mean dosage of 24.8 mg in 5.0 ± 1.3 injections) as an adjunct did not significantly improve the long-term filtration outcome of PGTP in POAG patients.

AB - Purpose: To evaluate the long-term effect of adjunctive subconjunctival 5-fluorouracil (5-FU) on the filtration outcome of primary glaucoma triple procedure (PGTP) in primary open-angle glaucoma (POAG) patients. Methods: Seventy-four POAG patients were randomly assigned to PGTP alone (36 patients) or PGTP with adjunctive subconjunctival 5-FU (5.0±1.3 injections of 5 mg each, total of 24.8 mg) (38 patients). After surgery, the patients were examined at regular intervals for intraocular pressure (IOP), visual acuity, medical therapy requirements, and complications. Surgical success was defined as IOP ≤20 mmHg on postoperative medication ≤1 without additional glaucoma surgery. Results: Over an average follow-up (±SD) of 45.3 ± 25.0 months, both 5-FU and control groups maintained significant improvement of IOP control and visual acuity. However, there were no statistically significant differences between the 5-FU and control groups with respect to postoperative IOP, number of glaucoma medications, visual acuity outcome, and success rate overall or in selected patients with one or more of the risk factors for filtration failure. Conclusions: The use of low-dose subconjunctival 5-FU (mean dosage of 24.8 mg in 5.0 ± 1.3 injections) as an adjunct did not significantly improve the long-term filtration outcome of PGTP in POAG patients.

UR - http://www.scopus.com/inward/record.url?scp=0031596450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031596450&partnerID=8YFLogxK

U2 - 10.1007/s004170050112

DO - 10.1007/s004170050112

M3 - Article

VL - 236

SP - 501

EP - 506

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 7

ER -